Iribarren ME, et al. Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma. P2520. ERS 2019, 28 sep.-2 okt. 2019, Madrid, Spanje.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties